Visceral leishmaniasis (VL; also known as kala-azar) is the most lethal form of leishmaniasis, inevitably requiring treatment to prevent mortality \[[@CIT0001]\]. Around 200000--400000 new cases of VL occur worldwide each year (data from 2004--2008 \[[@CIT0002]\]). Cases of VL have sharply decreased in South Asia following an elimination campaign \[[@CIT0003], [@CIT0004]\], leaving the Eastern Africa region with the highest burden worldwide, with 29400 to 56600 cases estimated annually \[[@CIT0002]\].

A limited number of drugs are available for VL treatment \[[@CIT0005]\] and all of them have limitations related to either toxicity, parenteral administration, cost, and/or a requirement of cold chain. In Eastern Africa, the World Health Organization recommended 17 days of combination treatment of sodium stibogluconate (20 mg/kg/day Sb^5+^) and paromomycin (11 mg base/kg/day) \[[@CIT0005]\]. This combination has an efficacy rate of 91.4% \[[@CIT0006]\], but requires 17 days of 2 injections, and antimonial is associated with infrequent but significant life-threatening toxicity (cardio-toxicity, acute pancreatitis) \[[@CIT0005]\].

Miltefosine, an alkylphosphocholine analogue initially developed as an anti-cancer drug, has reemerged as the only effective oral VL treatment \[[@CIT0007]\]. In initial trials performed in India, miltefosine at 2.5 mg/kg/day for 28 days had high efficacy rates (\>90% at 6 months follow-up) in patients aged ≥12 years \[[@CIT0008]\] and in children aged 2--11 \[[@CIT0009]\]. In Ethiopian adult VL human immunodeficiency virus--negative male patients (aged ≥15 years), miltefosine (100 mg/day for 28 days) achieved a 6-month cure rate of 75.6% (99/131), although 19.1% of participants were lost to follow-up. The efficacy for those who completed the 6-month follow-up was 93.4%, with a 5.7% relapse rate and 1 case of death \[[@CIT0010]\]. A phase II trial (LEAP 0208; NCT01067443) \[[@CIT0011]\] in Sudan and Kenya comparing miltefosine alone (2.5 mg/kg/day for 28 days) with miltefosine (2.5 mg/kg/day for 10 days) in combination with liposomal amphotericin B (10 mg/kg single dose) achieved 6-month cure rates of 72% and 77%, respectively. Although this trial produced discouraging efficacy data, it provided important pharmacokinetic data for miltefosine monotherapy in the Eastern African population, showing lower systemic miltefosine exposure in children (\<12 years) than in adults with conventional linear mg/kg miltefosine dosing \[[@CIT0011]\]. There was a corresponding lower cure rate in these children; cure rates after 6 months of treatment were 59% in children and 86% in adults (*P* = .05). The lower efficacy of miltefosine monotherapy in pediatric VL was also evident in previous studies in Nepal and India; children with VL had higher rates of failure (6.4% versus 3.4% in adults) \[[@CIT0009]\] and higher relapse risks \[[@CIT0012], [@CIT0013]\]. Both for Eastern Africa \[[@CIT0014]\] and Asia \[[@CIT0013], [@CIT0015]\], higher failure rates due to relapses were associated with lower miltefosine exposure \[[@CIT0015]\]. Model-based simulations of an allometric dosing regimen, based on non-linear scaling of the dose in children based on their fat-free mass, predicted a level of miltefosine exposure in children equivalent to that achieved in adults receiving conventional dosing \[[@CIT0015]\]. We tested this prediction in Eastern African children with VL, aiming to increase drug exposure and correspondingly increase the cure rate. Because the required allometric dosing involves oral doses exceeding conventional dosing, we also assessed its safety in children.

METHODS {#s6}
=======

Study Patients {#s7}
--------------

We recruited 30 children with primary VL, aged 4--12 years, at 2 clinical sites: Kacheliba, West Pokot County, Kenya, and Amudat, Karamoja sub-region, Uganda. All patients fulfilled the trial inclusion and exclusion criteria ([Supplementary Material](#sup1){ref-type="supplementary-material"}). They showed VL clinical signs and symptoms and had a confirmatory parasitological microscopic diagnosis. Their age varied between ≥4 and ≤12 years and they weighed \<30 kg. All had primary, non-severe VL (based on clinical and hematological parameters, as per exclusion criteria) and had not received anti-leishmanial drugs within the previous 6 months. None suffered severe malnutrition or any serious underlying disease or concomitant severe infection.

Study Drug {#s8}
----------

Miltefosine medication was Impavido in 10 mg and 50 mg capsules (Paladin Labs Inc., Montreal, Canada), in aluminium--aluminium blister foil packs.

Treatment and Procedures {#s9}
------------------------

Patients were hospitalized for screening, baseline procedures, and the 28-day treatment duration, and assessed during outpatient follow-ups on days 56 and 210 after the start of treatment. All patients received 28-day allometric miltefosine dosing twice daily after a meal, and were under observation by the nurse until 30 minutes after each administration to record any vomiting. The allometric dose was determined using the patient's sex and baseline height and weight, according to tables adapted from Dorlo and colleagues \[[@CIT0015]\] ([Supplementary Material](#sup1){ref-type="supplementary-material"}). Plasma samples were collected at screening; during treatment at days 1 (8 hours after first dose), 7, 14, 21, and 28 (before miltefosine administration); and at days 56 and 210 during the follow-up visits.

Trial Design {#s10}
------------

This was a phase II, open-label clinical trial, registered at the U.S. clinical trial registry (under NCT02431143) and conducted in accordance with the trial protocol, the International Conference on Harmonization guidelines for Good Clinical Practice, local regulations, and the Declaration of Helsinki. Ethical approvals were obtained from institutional ethics committees at the Kenya Medical Research Institute and at Makerere University, Uganda. Individual informed consent was obtained from parents/guardians and assent was obtained from participating patients, when applicable, as per country regulations.

The study objectives were to characterize the pharmacokinetics, safety, and efficacy of a miltefosine allometric regimen given for 28 days in Eastern African children with primary VL. The primary pharmacokinetic endpoints were total drug plasma exposure (area under the concentration time curve \[AUC\] from days 0 to 210) and plasma maximum concentration (C~max~).

The primary safety endpoints were frequency and severity of adverse events (AEs), serious adverse events (SAEs), and AEs necessitating treatment discontinuation. The secondary efficacy endpoints were cure rates at days 28 and 210 after the start of treatment (cure rate = proportion of patients recovering from clinical signs and symptoms of infection, having a negative microscopic reading for parasitaemia at day 28, and not requiring any rescue treatment up to day 210).

Plasma Miltefosine Bioanalysis {#s11}
------------------------------

Samples' storage and transportation conditions were monitored and maintained maximally at -20°C; no deviations were noted. Plasma miltefosine concentrations were quantified using liquid chromatography coupled to tandem mass spectrometry, as previously published \[[@CIT0016]\]. The performance of the bioanalysis is described in detail in the online [Supplementary Material](#sup1){ref-type="supplementary-material"}.

Pharmacokinetic Analyses {#s12}
------------------------

The plasma miltefosine data were managed using R (version 3.1.2). A standard 2-stage non-compartmental pharmacokinetic analysis was performed with the R package "ncappc" \[[@CIT0017]\]. Unless indicated otherwise, data are represented as median (range) and statistical tests were performed using a Mann-Whitney U-test.

Safety Assessment {#s13}
-----------------

Treatment safety was assessed at each visit by the routine recording of AEs that occurred since the previous visit; blood sampling for measurements of hematological and clinical chemistry parameters; and assessment of vital signs and physical condition. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 and clinically-relevant values were recorded.

Clinical Assessment of Efficacy {#s14}
-------------------------------

The clinical assessment of VL was performed at screening; on days 3, 7, 14, 21, and 28 of treatment; and on follow-up days 56 and 210. This involved measurements of axillary temperature, the size of the spleen and liver, and body weight. VL symptoms were also recorded. Parasitological assessments were performed at baseline and on day 28, using microscopic examinations of spleen aspirate or, under specific circumstances (see Study Protocol in online [Supplementary Methods](#sup1){ref-type="supplementary-material"}), bone marrow aspirates. A cure at the end of treatment (day 28) was defined as the absence of clinical signs and symptoms of VL (patient afebrile, spleen size reduced, and improvement of symptoms and hematological parameters) and the microscopic absence of parasites from the spleen or bone marrow aspirate. A definitive cure at day 210 (6 months) was defined as the absence of signs and symptoms of VL (no fever, reduced spleen size, hematological parameters recovered, and weight gained) and having not required any rescue treatment during the trial.

Statistical Analyses {#s15}
--------------------

The minimal sample size was based on the pharmacokinetic clinical trial simulations for the primary pharmacokinetic endpoint, using the method of Dorlo and colleagues \[[@CIT0018]\]. Including potential non-compliance, this provided a trial sample of 30 patients. For the primary pharmacokinetic endpoint, plasma miltefosine concentrations were measured in all patients receiving at least 1 miltefosine dose. All patients who were administered the first dose of miltefosine constituted the safety population. The primary population for efficacy analysis at days 28 and 210 was the intention-to-treat population (ITT). The per-protocol (PP) population included patients with no pre-specified major protocol deviations relating to treatment compliance and baseline exclusion criteria.

Descriptive analyses were used for patient characteristics and biological data. Categorical variables were summarized using proportions. Continuous variables are presented as means (standard deviation) and medians (interquartile range). Box plots are used to present laboratory parameters and spleen sizes. The time to relief of fever was analyzed using a Kaplan-Meier curve. For efficacy analyses, the primary analysis population at days 28 and 210 was the ITT population. Furthermore, a PP analysis was also performed. The STATA version 13.1 program \[[@CIT0019]\] was used for data analysis.

RESULTS {#s16}
=======

Patients {#s17}
--------

Out of 158 suspected VL cases, 30 subjects were enrolled; their disposition during the trial is shown in [Figure 1](#F1){ref-type="fig"}. Patients were excluded for various reasons, but mostly (87/158) because of age. Of those enrolled, 3 required rescue treatment: 1 during miltefosine treatment and 2 during the follow-up. The trial was completed without any loss to follow‐up. The ITT and PP populations were of identical sizes (n = 30).

![Disposition of patients.](ciy74701){#F1}

The age distribution of the children was evenly spread between 4 and 12 years ([Table 1](#T1){ref-type="table"}). All children had fever and most had abdominal swelling (96.7%), mucosal pallor (96.7%), and splenomegaly (93%). Most were of normal weight, with 36.7% underweight and none overweight, but 63.3% had lost weight since the disease onset, with 53.3% having muscle wasting and 26.7% having appetite loss.

###### 

Patients' Baseline Characteristics

  --------------------------------------------------------- -------------------- ---------------------
  **Demographics**                                          **n (%**)            
   Number of patients                                       30 (100)             
   Aged 4--7 years                                          16 (53.3)            
   Aged 8--12 years                                         14 (46.7)            
   Females/males                                            8 (26.7)/22 (73.3)   
                                                            **Mean ± SD**        **Median, IQR**
   Age (years)                                              7.7 ± 2.1            7.0, 6.0--9.0
   Weight (kg)                                              21.7 ± 4.2           21.8, 19.0--26.0
  **Nutritional status** ^a^                                n (%)                
   Underweight                                              11 (36.7)            
   Normal                                                   19 (63.3)            
   Overweight                                               0 (0.0)              
  **Vital signs**                                           **Mean ± SD**        **Median, IQR**
   Heart rate (beats/min)                                   113.9 ± 18.8         113.5, 100.0--122.0
   Systolic BP (mm Hg)                                      97.8 ± 8.9           97.5, 89.0--106.0
   Diastolic BP (mm Hg)                                     59.9 ± 9.3           59.5, 53.0--66.0
   Temperature (°C)                                         37.0 ± 1.3           36.6, 36.1--37.9
  **Signs and symptoms** (referred by the patient)          n (%)                
   Fever                                                    30 (100.0)           
   Abdominal swelling                                       29 (96.7)            
   Loss of appetite                                         8 (26.7)             
   Weight loss                                              19 (63.3)            
   Diarrhea                                                 0 (0.0)              
   Coughing                                                 14 (46.7)            
   Epistaxis                                                7 (23.3)             
   Other bleeding signs                                     0 (0.0)              
   Jaundice                                                 1 (3.3)              
  **Clinical characteristics** (per physical examination)   n (%)                
   Mucosal pallor                                           29 (96.7)            
   Cervical lymphadenopathy                                 4 (13.3)             
   Jaundice                                                 0 (0.0)              
   Axillary lymphadenopathy                                 2 (6.7)              
   Inguinal lymphadenopathy                                 1 (3.3)              
   Muscle wasting                                           16 (53.3)            
   Post--Kala-azar dermal leishmaniasis                     0 (0.0)              
   Other significant systemic characteristics               0 (0.0)              
                                                            **Mean ± SD**        
   Spleen size (cm)                                         9.1 ± 4.3            
   Liver size (cm)                                          2.6 ± 2.0            
  **Hematology** ^b^                                        **Mean ± SD**        **Median, IQR**
   Hemoglobin (g/dL)                                        7.0 ± 1.1            6.9, 6.1--8.0
   Hematocrit (%)                                           23.0 ± 3.9           22.9, 19.1--26.5
   White‐cell count (x10^3^/µL)                             2.7 ± 1.2            2.7, 1.8--3.0
   Neutrophils (%)                                          36.1 ± 11.6          37.0, 28.0--43.0
   Lymphocytes (%)                                          58.2 ± 10.5          60.0, 49.0--64.0
   Monocytes (%)                                            5.7 ± 4.1            6.0, 2.0--9.0
   Eosinophils (%)                                          0.03 ± 0.18          \-
   Platelets (x10^3^/µL)                                    128.4 ± 82.7         107.0, 83.0--139.0
  **Clinical chemistry** ^c^                                **Mean ± SD**        **Median, IQR**
   Aspartate aminotransferase (U/L)                         48.7 ± 36.2          35.0, 29.0--50.0
   Alanine aminotransferase (U/L)                           26.6 ± 18.6          20.5, 14.0--36.0
   Total bilirubin (μmol/L)                                 5.7 ± 3.1            5.0, 3.0--6.8
   Creatinine (μmol/L)                                      47.4 ± 8.4           47.5, 41.0 to 53.0
  --------------------------------------------------------- -------------------- ---------------------

Abbreviations: BP, blood pressure; IQR, interquartile range; SD, standard deviation; WHO, World Health Organization.

^a^Based on WHO standardized nutritional status. Children with severe malnutrition were excluded (z‐score \<−3). For children aged \<5 years, weight for height was used: children were considered underweight when their z‐score \<−2 and overweight when their z‐score \>2. For children aged 5--12 years, body mass index for age was used: children were considered underweight when their z‐score \<−2 and overweight when their z‐score \>1.

^b^The following reference ranges were used for hematology parameters: hemoglobin (10--14.5 g/dL), white blood cell count (4--10 x10^3^/µL), neutrophils (42--75%), and platelets (120--400 x10^3^/µL).

^c^The following reference ranges were used for clinical chemistry parameters: aspartate aminotransferase (22--60 U/L), alanine aminotransferase (12--45 U/L), total bilirubin (\<17 µmol/L), and creatinine (17.6--88 µmol/L)

Pharmacokinetics {#s18}
----------------

The patients received a median daily allometric miltefosine dose of 3.2 mg/kg/day (range, 2.7--3.9 mg/kg/day). The quantitative analysis of plasma miltefosine met standard Food and Drug Administration criteria, with accuracies and precisions within ±15% and ≤15%, respectively. Excluding pre-treatment samples, which were all below the lowest level of quantification, as expected, a total of 206 samples were collected from 30 patients, as per protocol. We excluded 3 samples from the data analysis, since a steep (\>70%) decrease in miltefosine concentration was observed during treatment, which was physiologically improbable due to the long elimination half-life of miltefosine \[[@CIT0018]\].

Observed Miltefosine Exposure After Allometric Dosing {#s19}
-----------------------------------------------------

Miltefosine plasma concentration-time profiles after allometric dosing are depicted in [Figure 2](#F2){ref-type="fig"}. Of the 3 patients who experienced treatment failure or relapse, 2 had substantially lower miltefosine accumulations than the cured patients ([Figure 2](#F2){ref-type="fig"}). Unexpectedly, for 37% of patients, the miltefosine concentrations plateaued or even decreased between days 14 and 21 (change in concentration between -19% and +10%), after which concentrations increased \>18% (range 18--58%) at day 28.

![Individual plasma miltefosine concentration-time profiles: the gray lines indicate the patients who were cured of visceral leishmaniasis, the full black lines indicate the 2 patients who required rescue treatment during follow-up, and the dashed black line indicates the patient who initially failed on treatment. The vertical dotted line shows the end of treatment (day 28).](ciy74702){#F2}

Descriptive Comparison of Allometric Miltefosine Dosing with Historical, Conventional-dosing Data {#s20}
-------------------------------------------------------------------------------------------------

Miltefosine exposure in the current allometric study was compared with pediatric data for conventional linear dosing (from the LEAP 0208 trial \[[@CIT0011]\]). Due to differences in age limits for inclusion, the LEAP 0208 cohort (n = 21) had a higher median age (10 years, range 7--12 years) and a higher median body weight (24 kg, range 16--34 kg) \[[@CIT0011]\]. As there was no difference in exposure between the 4--6 year and 7--12 year age groups in the present study, all patients with available pharmacokinetics (PK) data were included in this comparison with the LEAP 0208 trial.

Although not statistically significant, children receiving allometric dosing showed a trend (*P* = .07) for much more rapid miltefosine accumulation than children on conventional dosing, with median day-7 plasma concentrations of 5.88 µg/mL (range 0.66--14.3 µg/mL) versus 2.67 µg/mL (range 0.70--12.8), respectively. However, the median total exposure was only slightly increased with allometric dosing, resulting in a 6% and 8% higher C~max~ and AUC~0-210~, respectively ([Table 2](#T2){ref-type="table"}). For comparison, the observed total exposure after allometric dosing was still lower than that in adults receiving the conventional linear dosing (median non-compartmental analysis AUC~0-210~ 582 versus 836 µg∙day/mL, respectively; data not published). The variability (coefficient of variation%) of miltefosine C~max~ values was 2-fold lower with allometric dosing (15.7%) than with conventional dosing (30.5%) when comparing the pediatric populations. Similarly, AUC~0-210~ values were less variable with allometric dosing than with conventional dosing ([Table 2](#T2){ref-type="table"}). Furthermore, the proportion of patients with a C~max~ lower than the target of 17.9 µg/mL was 14.8% in patients treated with allometric dosing, as compared to 28.6% in conventional dosing ([Table 2](#T2){ref-type="table"}).

Safety {#s21}
------

[Table 3](#T3){ref-type="table"} summarizes the frequency of AEs recorded during the trial and [Table 4](#T4){ref-type="table"} lists the AEs according to the Medical Dictionary for regulatory activities (MedDRA) categorization system (System Organ Class/Preferred Term), their relationship to the study drug, and severity (as per CTCAE v4.0). A total of 110 treatment-emergent adverse events (TEAEs) were reported in 30 subjects. All patients had at least 1 TEAE, with the most frequent being anaemia, neutropenia, malaria, and upper respiratory infection. There were 13 patients (43%) that presented a total of 19 TEAEs related to the study drug, which are referred to as treatment-emerging adverse drug reactions (TEADRs). Among these, the most common were neutropenia and vomiting, which were reported in 20% and 17% of patients, respectively. No patient discontinued treatment due to an AE, and cases of vomiting were not associated with treatment compliance failure. There were 5 (4.5%) Grade 4 TEAEs reported (1 anaemia, 4 neutropenia). The Grade 4 neutropenia cases (\<500/mm^3^) occurred in subjects with Grade 3 low neutrophil counts at baseline that worsened in severity after the treatment initiation. The majority of neutropenia cases occurred during the first days of treatment, were temporary and asymptomatic, resolved spontaneously, and did not require any intervention. Only mild (Grade 1 CTCAE) increases in aspartate aminotransferase and alanine aminotransferase levels were observed. Creatinine levels remained stable for all subjects during the treatment period, and only 1 Grade 2 increase was observed. These Grade 1 and 2 increases were not considered clinically significant and not reported as AEs by the investigator.

###### 

Frequency of Adverse Events

  ------------------------------------------------------------------- ----------
  Patients enrolled and receiving at least 1 dose, number (%)         30 (100)
  Patients with at least 1 AE, serious or not, number (%)             30 (100)
  Patients with adverse drug reaction, number (%)                     13 (43)
  Patients with an AE not related to the study drug, number (%)       30 (100)
  Patients with at least 1 serious AE, number (%)                     2 (7)
  TEADR, number                                                       19
  TEADR per patient, median (range)                                   1 (1--6)
  Patients whose treatment was stopped due to a TEAE, number (%)      0 (0)
  Patients experiencing ≥1 episode of repeated vomiting, number (%)   0 (0)
  Patients experiencing ≥1 CTC grade 3 or 4 TEADR, number (%)         5 (17)
  ------------------------------------------------------------------- ----------

Abbreviations: AE, adverse event; CTC, Common Terminology Criteria; TEAE, treatment-emergent adverse events; TEADR, treatment-emerging adverse drug reaction.

###### 

List of Treatment-Emergent Adverse Events by Relatedness to Study Drug and Severity

  System Organ Class                                     Preferred MedDRa Term                    Total   Study Drug Relatedness   Grade of Severity                
  ------------------------------------------------------ ---------------------------------------- ------- ------------------------ ------------------- --- --- ---- ---
  Blood and lymphatic system disorders                   Anaemia                                  14      13                       1                   0   1   12   1
                                                         Leukopenia                               5       5                        0                   0   0   5    0
                                                         Neutropenia                              1       7                        7                   0   1   9    4
                                                         Thrombocytopenia                         3       3                        0                   0   0   3    0
  Gastrointestinal disorders                             Constipation                             1       1                        0                   1   0   0    0
                                                         Diarrhea                                 3       1                        2                   3   0   0    0
                                                         Hyperacidity                             1       1                        0                   1   0   0    0
                                                         Nausea                                   1       0                        1                   1   0   0    0
                                                         Rectal prolapse                          1       0                        1                   1   0   0    0
                                                         Vomiting                                 6       1                        5                   6   0   0    0
  General disorders and administration site conditions   Hypothermia                              1       1                        0                   0   1   0    0
                                                         Puncture site pain                       1       1                        0                   1   0   0    0
                                                         Pyrexia                                  6       5                        1                   1   3   2    0
  Infections and infestations                            Abscess                                  2       2                        0                   0   2   0    0
                                                         Ascariasis                               1       1                        0                   0   1   0    0
                                                         Bronchopneumonia                         1       1                        0                   0   1   0    0
                                                         Conjunctivitis                           1       1                        0                   1   0   0    0
                                                         Fungal infection                         1       1                        0                   1   0   0    0
                                                         Herpes simplex                           1       1                        0                   1   0   0    0
                                                         Lower respiratory tract infection        2       2                        0                   1   1   0    0
                                                         Malaria                                  12      12                       0                   6   6   0    0
                                                         Otitis media                             3       3                        0                   0   3   0    0
                                                         Tinea capitis                            4       4                        0                   2   2   0    0
                                                         Tonsillitis                              1       1                        0                   0   1   0    0
                                                         Upper respiratory infection              12      12                       0                   9   3   0    0
                                                         Varicella                                1       1                        0                   0   1   0    0
                                                         Wound infection                          1       1                        0                   0   1   0    0
  Injury, poisoning, and procedural complications        Transfusion Reaction                     1       1                        0                   0   1   0    0
  Investigations                                         Blood bilirubin unconjugated increased   1       0                        1                   0   1   0    0
  Nervous system disorders                               Headache                                 1       1                        0                   0   1   0    0
  Respiratory, thoracic, and mediastinal disorders       Cough                                    3       3                        0                   3   0   0    0
                                                         Epistaxis                                2       2                        0                   1   1   0    0
                                                         Oropharyngeal pain                       1       1                        0                   1   0   0    0
  Skin and subcutaneous tissue disorders                 Rash                                     1       1                        0                   0   1   0    0

Abbreviation: TEAEs, treatment-emergent adverse events.

There were 2 patients that each had a SAE. The first had a case of "transfusion reaction" that was considered an important medical event by the investigator, occurring on day 203 after the treatment start. The other case was life-threatening anaemia (PT), occurring on day 19. This patient was later assessed as an initial failure. Both SAEs were reported as unrelated to miltefosine treatment by the investigator, and the patients fully recovered.

Efficacy {#s22}
--------

Each enrolled patient belonged to both the PP and ITT populations. The 28-day and 210-day cure rates were 96.7% (95% confidence interval, 83-100%; 29/30 patients) and 90% (95% confidence interval, 74-98%; 27/30 patients), respectively. There were 3 patients that received Ambisome rescue treatment: 1 at day 25 (initial failure), 1 at day 168 (relapse), and 1 at day 206 (relapse).

The clinical response was observed in several parameters, including spleen and liver sizes, which decreased progressively during the treatment and follow-up period (up to day 210; [Figure 3](#F3){ref-type="fig"}). Hemoglobin and hematocrit increased towards normal levels by the end of treatment and remained normal during follow-up ([Figure 3](#F3){ref-type="fig"}). Fever was cleared in nearly all patients by day 14 of treatment, and in all patients by the end of treatment (see [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Weight gain was observed for all patients, with an 8% average increase at the end of the study compared to baseline.

![Box plots of selected efficacy clinical parameters during treatment (day 0 to day 28) and follow-up. The box plots represent the interquartile ranges, the whiskers represent minimum and maximum values, and the dots outside the whiskers are outlier values. Red lines in the hemoglobin figure represent the lower and upper limits of normal.](ciy74703){#F3}

DISCUSSION {#s23}
==========

The present study is the first to assess the pharmacokinetics, safety, and efficacy profile of miltefosine in pediatric VL patients treated with an allometric dosing regimen, which provided a 28% higher median daily dose than conventional linear dosing. Our pharmacokinetic data indicate more rapid accumulation after allometric dosing in the first weeks of treatment, with both C~max~ and AUC~0-210~ being only slightly increased (6% and 8%, respectively), probably due to a plateau in accumulation in the third week of treatment, implying a non-linear dose proportionality of miltefosine pharmacokinetics (see online [Supplementary Materials](#sup1){ref-type="supplementary-material"}).

Variability in exposure decreased almost 2-fold with the allometric dosing compared to the conventional dosing (as shown by the spread of C~max~ and of AUC~0-210~; [Table 2](#T2){ref-type="table"}). The low variability observed in miltefosine concentrations between patients can also be seen in [Figure 2](#F2){ref-type="fig"}. These data indicate that allometric dosing of miltefosine allows a more consistent systemic exposure to the drug treatment than linear dosing. The individual patients' C~max~ values from the non-compartmental pharmacokinetic analyses ([Table 2](#T2){ref-type="table"}) also indicate that fewer children (15%) on allometric dosing than children (29%) on linear dosing had plasma miltefosine levels below the threshold of 17.9 μg/mL, which has been previously shown to be related to a higher probability of disease relapse \[[@CIT0021]\]. Additionally, miltefosine concentrations in the first week of treatment were highly increased after allometric dosing, as compared to linear dosing, when comparing the pediatric populations (data not shown). This may be pivotal, both in terms of efficacy as well as driving the emergence of drug resistance, given that the parasite biomass is highest at this stage of treatment.

###### 

Comparison of Noncompartmental Pharmacokinetic Parameters After Conventional Linear and Allometric Dosing in Separate Groups of Miltefosine-treated Eastern African Pediatric Patients With Visceral Leishmaniasis

                                       Conventional Dosing   Allometric Dosing                                 
  ------------------------------------ --------------------- ------------------- ------- -------- ------------ -------
  Number of patients                   21                    27                                                
  Demographics                         LEAP0208              LEAP0714^a^                                       
  Age in years, median (range)         10 (7--12)            7 (4--12)                                         
  Weight in kg, median (range)         24 (16--34)           22 (13--30)                                       
  Height in meters, median (range)     1.35 (1.07--1.53)     1.25 (0.99--1.45)                                 
  Gender, % female                     24%                   27%                                               
  Pharmacokinetic parameters                                                                                   
                                       Median                Range               RSD     Median   Range        RSD
  AUC~0-210~, μg\*day/mL               539                   295--1110           35.3%   582      392--817     18.9%
  C~max~,μg/mL                         19.9                  14.4--37.7          30.5%   21.0     15.5--28.6   15.7%
  C~max~ \< 17.9 µg/mL target, n (%)   6/21 (28.6%)          4/27 (14.8%)                                      

Data are from LEAP 0208 and LEAP 0714 Trials: 1 outlier data point was excluded from analyses of each cohort.

Abbreviations: AUC~0-210~, area under the curve; C~max~, plasma maximum concentration; RSD, relative standard deviation.

^a^Data from 3 patients were excluded: 2 patients had an anomalous decline in miltefosine values between days 21 and 28 and 1 patient had no values after day 21.

The improved miltefosine pharmacokinetics could at least partially explain the much improved 6-month cure rate (90%), compared to the rate we previously reported in Eastern African children (59%, LEAP 0208) \[[@CIT0011]\]. In fact, the efficacy observed in children treated with allometric dosing was similar to that observed in adults (86%) treated with a 28-day conventional treatment regimen \[[@CIT0011]\], despite the lower average drug exposure compared to adults.

The present non-compartmental analysis is limited by the sparse sampling and the observed pharmacokinetic non-linearity, which may, for example, cause an underestimation of exposure during treatment and an overestimation during follow-up. We are currently developing a model-based analysis of pharmacokinetic data pooled from several trials, to characterize the observed non-linearities in pediatric VL patients in Eastern Africa.

Our findings are an important basis for the further development of miltefosine as an effective oral medicine for use in combination treatment of VL in Eastern African children. We show that allometric miltefosine dosing in children is safe and more effective than conventional dosing. Further development of miltefosine should adopt allometric dosing in patients weighing ˂30 kg. A phase III trial is envisaged to assess combining an allometric regimen of miltefosine with paromomycin in VL patients in Eastern Africa, as compared to sodium stibogluconate and paromomycin. Positive results would provide a basis for the provision of an alternative treatment that is more patient friendly and requires shorter hospitalizations than the current standard treatment, by replacing the much more toxic sodium stibogluconate with oral miltefosine. Miltefosine allometric dosing would be of potential benefit beyond Eastern Africa, as there is also an urgent need in South America and Asia for more tolerable and more convenient oral treatments for children affected by cutaneous leishmaniasis and post--kala-azar dermal leishmaniasis.

Supplementary Data {#s24}
==================
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